Abstract:Cancer is a highly aggressive and devastating disease, and impediments to a cure arise not just from cancer itself. Targeted therapies are difficult to achieve since the majority of cancers are more intricate than ever imagined. Mainstream methodologies including chemotherapy and radiotherapy as routine clinical regimens frequently fail, eventually leading to pathologies that are refractory and incurable. One major cause is the gradual to rapid repopulation of surviving cancer cells during intervals of multiple-dose administration. Novel stress-responsive molecular pathways are increasingly unmasked and show promise as emerging targets for advanced strategies that aim at both de novo and acquired resistance. We highlight recent data reporting that treatments particularly those genotoxic can induce highly conserved damage responses in non-cancerous constituents of the tumor microenvironment (TMEN). Master regulators, including but not limited to NF-kB and C/EBP-beta, are implicated and their signal cascades culminate in a robust, chronic and genome-wide secretory program, forming an activated TMEN that releases a myriad of soluble factors. The damage-elicited but essentially off target and cell non-autonomous secretory phenotype of host stroma causes adverse consequences, among which is acquired resistance of cancer cells. Harnessing signals arising from the TMEN, a pathophysiological niche frequently damaged by medical interventions, has the potential to promote overall efficacy and improve clinical outcomes provided that appropriate actions are ingeniously integrated into contemporary therapies. Thereby, anticancer regimens should be well tuned to establish an innovative clinical avenue, and such advancement will allow future oncological treatments to be more specific, accurate, thorough and personalized.

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

The tumor microenvironment: a key player in multidrug resistance in cancer

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)

Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment

Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Role of tumor microenvironment in cancer progression and therapeutic strategy

Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy

New horizons in tumor microenvironment biology: challenges and opportunities

Microenvironmental regulation of therapeutic response in cancer

Tackling the Tumor Microenvironment： What Challenge Does It Pose to Anticancer Therapies？

Mechanisms of Cancer Resistance to Immunotherapy

Tumor Microenvironment‐Enabled Nanotherapy

Tumor microenvironment as a complex milieu driving cancer progression: a mini review